Health
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. “Activation of CHOP is a significant step forward for the Recessive dystrophic epid
About this update from Abeona Therapeutics Inc.
[{"type":"image","alt":"Abeona Therapeutics Inc.","displaySize":"","headline":null,"caption":"Abeona Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":256,"height":181,"url":"https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HRLXSFjGp4rPpBccsBYqcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5Nw--/https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d","width":256,"height":181},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/HRLXSFjGp4rPpBccsBYqcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5Nw--/https://media.zenfs.com/en/globenewswire.com/29420b6ac7ca8949eb7c2a775811595d","width":256,"height":181}},"lazy":false},{"type":"text","content":"CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets.","length":416,"tagName":"p"},{"type":"text","content":"“Activation of CHOP is a significant step forward for the Recessive dystrophic epidermolysis bullosa (RDEB) community expanding access to ZEVASKYN in the east coast,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of Abeona. “We are excited to collaborate with Dr. Marissa J. Perman and her team, global leaders in pediatric care and pioneers in gene and cell therapy innovation, to enable more patients an opportunity to receive ZEVASKYN treatment.”","length":458,"tagName":"p"},{"type":"text","content":"“CHOP is proud to be named a treatment center for ZEVASKYN,” said Marissa J. Perman, MD, Section Chief of Dermatology and Director of the Epidermolysis Bullosa Multidisciplinary Clinic at Children's Hospital of Philadelphia. “This designation underscores our dedication to delivering leading-edge care and expanding access to promising new therapies that have the potential to enhance quality of life for patients with RDEB and their families.”","length":448,"tagName":"p"},{"type":"text","content":"For more information about receiving ZEVASKYN treatment at CHOP, contact the Epidermolysis Bullosa Multidisciplinary Clinic...